TARGACEPT, INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
- Website
- http://www.targacept.com
TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia
- First Posted Date
- 2009-10-28
- Last Posted Date
- 2013-09-13
- Lead Sponsor
- Targacept Inc.
- Target Recruit Count
- 184
- Registration Number
- NCT01003379
- Locations
- ๐บ๐ธ
Synergy Clinical Research Center, National City, California, United States
๐บ๐ธCollaborative Neuroscience Network, Inc LA County, Torrance, California, United States
๐บ๐ธAltanta Center for Medical Research, Atlanta, Georgia, United States
TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2013-09-13
- Lead Sponsor
- Targacept Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT00899977
- Locations
- ๐บ๐ธ
Piedmont Medical Research, Winston-Salem, North Carolina, United States
TC-5214 as add-on the Treatment of Major Depressive Disorder
Phase 2
Completed
- Conditions
- Major Depressive DisorderDepression
- Interventions
- First Posted Date
- 2008-06-06
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Targacept Inc.
- Target Recruit Count
- 574
- Registration Number
- NCT00692445
- Locations
- ๐บ๐ธ
Aurora Clinical Trials, Miami, Florida, United States
๐บ๐ธCommunity Research, Cincinnati, Ohio, United States
๐บ๐ธUT Southwestern Medical Center, Dallas, Texas, United States
Flexible Dose Titration Add-on Study to Treat Major Depressive Disorder
- First Posted Date
- 2008-01-15
- Last Posted Date
- 2008-01-15
- Lead Sponsor
- Targacept Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT00593879
A Safety and Tolerability Single Ascending Dose Study in Healthy Volunteers
- First Posted Date
- 2007-12-31
- Last Posted Date
- 2008-07-18
- Lead Sponsor
- Targacept Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT00583544
- Locations
- ๐ซ๐ท
Forenap Pharma, Rouffache, France
A Safety and Efficacy Study of Ispronicline (TC-1734-112) in Subjects With Age Associated Memory Impairment (AAMI)
Phase 2
Completed
- Conditions
- Age-Related Memory Disorders
- First Posted Date
- 2005-04-29
- Last Posted Date
- 2008-07-18
- Lead Sponsor
- Targacept Inc.
- Target Recruit Count
- 174
- Registration Number
- NCT00109564
- Locations
- ๐บ๐ธ
Pivotal Research Center, Peoria, Arizona, United States
๐บ๐ธRadiant Research, Salt Lake City, Utah, United States
๐บ๐ธNeuropsychiatric Research Center of SW Florida, Fort Meyers, Florida, United States